← Leaderboards
Todd D Gould
Baltimore Va Medical Center
$11,245,492
Attributed
$12,094,617
Total exposure
12
Grants
11
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.2M · FY2009–25$2M$1.5M$1M$500K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$12,094,617 · 9
VA$0 · 3
By mechanism
R01$9,047,586 · 2
R21$2,523,250 · 6
P30$523,781 · 1
I01$0 · 3
Top collaborators
- Yen Pei Christy Chang2 shared
- Sarah Michelle Clark2 shared
- Laszlo Prokai2 shared
- Robert Schwarcz2 shared
Others in their field
Top investigators on “Mediating”
- Bambra Strokes · Ppd Development Lp$526,656,217
- Lawrence Corey · Fred Hutchinson Cancer Center$493,822,581
- Barton F Haynes · Duke University$295,802,493
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$286,700,869
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$176,977,598
- Dan H. Barouch · Fred Hutchinson Cancer Center$122,734,499
Research focus
MediatingMental DepressionTreatment EfficacyPre-ClinicalPharmaceutical PreparationsBehavioralBrainFutureBehaviorPropertyPharmacologyTherapeutic EffectAntidepressive AgentsAnimal ModelMoodsAnhedoniaAnestheticsBaseKetamineResistanceSymptomsDepressive SymptomsLeadExperimental Study
Grant awards (50)
Therapeutic Efficacy of Ketamine Metabolites for Depression Treatment$666,651
R01 · FY2025 · MH · contact PI
Therapeutic Efficacy of Ketamine Metabolites for Depression Treatment$60,205
R01 · FY2025 · MH · contact PI
Estradiol treatment of stress-related psychiatric disorders in Veterans$0
I01 · FY2025 · VA · contact PI
Therapeutic Efficacy of Ketamine Metabolites for Depression Treatment$666,651
R01 · FY2024 · MH · contact PI
Therapeutic Efficacy of Ketamine Metabolites for Depression Treatment$60,211
R01 · FY2024 · MH · contact PI
Estradiol treatment of stress-related psychiatric disorders in Veterans$0
I01 · FY2024 · VA · contact PI
Therapeutic Efficacy of Ketamine Metabolites for Depression Treatment$599,987
R01 · FY2023 · MH · contact PI
Hydroxynorketamine for the Treatment of PTSD and Anhedonia$0
I01 · FY2023 · VA · contact PI
Estradiol treatment of stress-related psychiatric disorders in Veterans$0
I01 · FY2023 · VA · contact PI
Therapeutic Efficacy of Ketamine Metabolites for Depression Treatment$633,319
R01 · FY2022 · MH · contact PI
Hydroxynorketamine for the Treatment of PTSD and Anhedonia$0
I01 · FY2022 · VA · contact PI
Therapeutic Efficacy of Ketamine Metabolites for Depression Treatment$666,651
R01 · FY2021 · MH · contact PI
Mechanisms of sustained anti-neuroinflammatory actions of (2R, 6R)-hydroxynorketamine (HNK)$193,125
R21 · FY2021 · AI
Targeting the inflammatory response to treat post-traumatic anxiety and depression.$0
I01 · FY2021 · VA · contact PI
Hydroxynorketamine for the Treatment of PTSD and Anhedonia$0
I01 · FY2021 · VA · contact PI
Therapeutic Efficacy of Ketamine Metabolites for Depression Treatment$865,601
R01 · FY2020 · MH · contact PI
Mechanisms of sustained anti-neuroinflammatory actions of (2R, 6R)-hydroxynorketamine (HNK)$231,750
R21 · FY2020 · AI
Model Development and Phenotyping Core$105,884
P30 · FY2020 · NR · contact PI
Targeting the inflammatory response to treat post-traumatic anxiety and depression.$0
I01 · FY2020 · VA · contact PI
Hydroxynorketamine for the Treatment of PTSD and Anhedonia$0
I01 · FY2020 · VA · contact PI
Therapeutic Efficacy of Ketamine Metabolites for Depression Treatment$567,763
R01 · FY2019 · MH · contact PI
Therapeutic Efficacy of Ketamine Metabolites for Depression Treatment$299,704
R01 · FY2019 · MH · contact PI
Model Development and Phenotyping Core$103,092
P30 · FY2019 · NR · contact PI
Hydroxynorketamine for the Treatment of PTSD and Anhedonia$0
I01 · FY2019 · VA · contact PI
Targeting the inflammatory response to treat post-traumatic anxiety and depression.$0
I01 · FY2019 · VA · contact PI
Therapeutic Efficacy of Ketamine Metabolites for Depression Treatment$479,815
R01 · FY2018 · MH · contact PI
Therapeutic Efficacy of Ketamine Metabolites for Depression Treatment$169,950
R01 · FY2018 · MH · contact PI
Model Development and Phenotyping Core$106,126
P30 · FY2018 · NR · contact PI
Therapeutic Efficacy of Ketamine Metabolites for Depression Treatment$89,999
R01 · FY2018 · MH · contact PI
Therapeutic Efficacy of Ketamine Metabolites for Depression Treatment$572,492
R01 · FY2017 · MH · contact PI
Therapeutic Efficacy of Ketamine Metabolites for Depression Treatment$153,400
R01 · FY2017 · MH · contact PI
Model Development and Phenotyping Core$102,884
P30 · FY2017 · NR · contact PI
Therapeutic Efficacy of Ketamine Metabolites for Depression Treatment$540,240
R01 · FY2016 · MH · contact PI
Model Development and Phenotyping Core$105,795
P30 · FY2016 · NR · contact PI
Therapeutic Efficacy of Ketamine Metabolites for Depression Treatment$92,377
R01 · FY2016 · MH · contact PI
Regulatory Role of CACNA1C Intronic DNA Variation Relevant to Psychiatric Disease$191,875
R21 · FY2015 · MH · contact PI
Suicide Endophenotypes and Molecular Mechanisms of Lithium Action$372,240
R01 · FY2014 · MH · contact PI
Regulatory Role of CACNA1C Intronic DNA Variation Relevant to Psychiatric Disease$230,250
R21 · FY2014 · MH · contact PI
An NMDA Glycine Site Antagonist for the Treatment of Major Depressive Disorder$191,875
R21 · FY2014 · MH · contact PI
Role of Brain Estradiol in the Treatment of Male Depression and Anxiety$189,750
R21 · FY2014 · MH · contact PI
Suicide Endophenotypes and Molecular Mechanisms of Lithium Action$357,350
R01 · FY2013 · MH · contact PI
Role of Brain Estradiol in the Treatment of Male Depression and Anxiety$239,375
R21 · FY2013 · MH · contact PI
An NMDA Glycine Site Antagonist for the Treatment of Major Depressive Disorder$230,250
R21 · FY2013 · MH · contact PI
Suicide Endophenotypes and Molecular Mechanisms of Lithium Action$372,240
R01 · FY2012 · MH · contact PI
Gonadal Hormones and Depression:The Role of Mood Disorder Risk Gene CACNA1C$187,500
R21 · FY2012 · MH · contact PI
Suicide Endophenotypes and Molecular Mechanisms of Lithium Action$372,240
R01 · FY2011 · MH · contact PI
Gonadal Hormones and Depression:The Role of Mood Disorder Risk Gene CACNA1C$225,000
R21 · FY2011 · MH · contact PI
Suicide Endophenotypes and Molecular Mechanisms of Lithium Action$388,500
R01 · FY2010 · MH · contact PI
A Genetic and Behavioral Model for the Human Response to Lithium$187,500
R21 · FY2010 · MH · contact PI
A Genetic and Behavioral Model for the Human Response to Lithium$225,000
R21 · FY2009 · MH · contact PI